NCT06427226 2026-04-17
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity
Tanta University
Phase 2 Recruiting
Clinical Trials
11 trialsNCT07436663 2026-02-27
SGLT2i/DPPi
Tanta University
Phase 4 Not yet recruiting
NCT07245069 2025-11-24
Alpaca
University Medical Centre Ljubljana
Phase 2 Recruiting
NCT06491680 2025-09-22
Cardiotoxicity in Breast Cancer Patients
Helwan University
Phase 4 Recruiting
NCT07070765 2025-07-23
SPRINT
University of Aberdeen
Phase NA Not yet recruiting
NCT05989347 2025-03-19
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
Yale University
Phase 1 Recruiting
NCT06304857 2024-12-04
PROTECTAA
4th Military Clinical Hospital with Polyclinic, Poland
Phase 3 Recruiting
NCT06711185 2024-12-02
DAPA-MYOCANCER
University of Campinas, Brazil
Phase 3 Recruiting
NCT04899349 2024-10-09
EPIK-B4
Novartis
Phase 2 Terminated
NCT06341842 2024-04-02
PROTECT
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase 2 Unknown
NCT05025735 2021-10-19
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
Saint Luke's Health System
Phase 2 Unknown